Sarcoma News and Research

RSS

Disrupted brain-immune signaling may help drive neurodegeneration

A Cell perspective argues that neurodegeneration can emerge from disrupted communication between neural and immune networks, with peripheral immunity, microglia, and gene-regulatory programs all shaping disease processes. The authors propose that restoring immune homeostasis and recalibrating neuroimmune circuits could create new therapeutic and diagnostic opportunities, while emphasizing that many mechanisms remain unresolved in humans.

24 Aug 2026

Scientists uncover safer way to tame cancer cell senescence

Stopping tumor growth is only half the battle. Rather than kill tumor cells, many cancer therapies can only push them into cellular senescence, a state in which cells stop dividing but do not die. These "undead" cells will continue to release signals that reshape the tumor environment.

20 Aug 2026

Study links delayed Ewing sarcoma growth to reduced Trk and IGF1R pathway markers

A new research paper was published in Volume 17 of Oncotarget on August 7, 2026, titled "Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers."

10 Aug 2026

Obscure X chromosome protein emerges as key driver in several cancers

A little-known protein encoded on the X chromosome is attracting growing attention for its potential role in cancer development and treatment.

5 Aug 2026

New cancer vaccine harnesses COVID-19 immune memory to fight tumors

In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history – a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination – into a powerful ally against cancer.

27 Jul 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Curcumin shows the best balance against cancer, study shows

Curcumin, berberine, and other plant-derived compounds have long attracted scientific interest because of their anti-inflammatory and anticancer properties.

22 Jul 2026

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

2 Jul 2026

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain tumors and the immune cells that help them grow.

1 Jul 2026

Gene fusion patterns refine classification of rare acute leukemias

Acute leukemias with chimeric fusion genes involving FET (FUS, EWSR1, and TAF15) family proteins and ETS (E26 transformation-specific)-like transcription factors often present with unique clinical and pathological characteristics.

27 Jun 2026

Targeting metabolic pathways could prevent relapse in KRAS-mutant cancers

Our cells rely on tightly regulated signaling pathways to control when they grow, divide, and survive. When these regulatory systems are disrupted, cells can acquire the ability to grow uncontrollably and become cancerous.

25 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

New funding supports cutting-edge research to combat cancers across South Texas

The University of Texas at San Antonio (UT San Antonio) and its academic health center, UT Health San Antonio, recently received over $2.7 million in new academic and prevention awards from the Cancer Prevention and Research Institute of Texas (CPRIT) to further its mission of combating cancers across South Texas.

2 Jun 2026

Scientists reveal why common pancreatic precancer lesions rarely turn deadly

Spatial and single-cell analyses of human donor pancreata showed that PanIN epithelial cells gradually acquire cancer-like molecular features, while their surrounding stromal and immune environment remains closer to normal pancreatic tissue. The findings suggest that delayed or incomplete microenvironmental reprogramming may help explain why most PanIN lesions remain indolent rather than progressing to pancreatic cancer.

24 May 2026

New biomarker predicts therapy response for hard-to-treat childhood cancers

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumor types.

22 May 2026

Specific gene fusion patterns tied to solitary fibrous tumor outcomes

Specific genetic fusion patterns in solitary fibrous tumors may help identify which patients face a higher risk of metastasis, recurrence and more aggressive disease behavior, according to new research that could improve how physicians assess and eventually treat this rare cancer.

21 May 2026

Scientists find unexpected immune pathways for mRNA cancer vaccines

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic.

17 Apr 2026

Scientists discover BRCA links to head and neck cancer risks

An international group led by researchers from the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have discovered associations between pathogenic variants of the BRCA 1 and 2 genes and four types of cancer. Published in ESMO Open, the findings expand the potential for personalized medicine to several cancer types that currently have limited treatment options and poor prognoses.

17 Apr 2026

ESMO and EURACAN call for policy action to standardize care for patients with rare cancers

Adherence to Clinical Practice Guidelines in the management of rare cancers remains inconsistent across Europe despite demonstrably improving patient outcomes, shows an analysis jointly conducted by ESMO and EURACAN, the European Reference Network (ERN) for rare cancers.

13 Mar 2026